Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acutolysin-A is a P-I class snake venom metalloproteinase (SVMP) isolated from the venom of the Five-pacer viper (Agkistrodon acutus) (UniProt: P18618). As a zinc-dependent endopeptidase, it specifically targets and degrades key components of the vascular basement membrane, such as type IV collagen, laminin, and fibronectin (PubMed: 9634601). This proteolytic activity leads to the weakening of capillary walls, resulting in the characteristic local and systemic hemorrhage observed in envenomated patients (PubMed: 15544518). Acutolysin-A is a primary target for therapeutic intervention using specific antivenoms, which neutralize the toxin to prevent further tissue damage and bleeding (PubMed: 11566310). Additionally, it serves as a model for studying the inhibition of metalloproteinases, with research exploring the efficacy of peptidomimetic inhibitors and chelating agents in mitigating venom-induced pathology (PubMed: 10454529).
Neutralization of proteolytic activity by binding to the catalytic zinc site or through antibody-mediated sequestration to prevent basement membrane degradation (PubMed: 11566310, 10454529).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acutolysin-A.